ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges

Zacks2024-12-19

Shares of Enzo Biochem, Inc. ENZ have tumbled 30.9% since the release of its earnings report for the quarter ended Oct. 31, 2024. This compares unfavorably with the S&P 500 Index's 2.9% decline over ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492742461?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_aMgtCHWD_AcEvdCSVRbpA--~B/aD00NDU7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62a1df11c94046acffed2654620317fb","is_english":true,"pubTime":"2024-12-19 21:48","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2492742461","market":"us","top_or_hot":-1,"title":"ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges","media":"Zacks","content":"<div>\n<p>Shares of Enzo Biochem, Inc. ENZ have tumbled 30.9% since the release of its earnings report for the quarter ended Oct. 31, 2024. This compares unfavorably with the S&P 500 Index's 2.9% decline over ...</p>\n\n<a href=\"https://finance.yahoo.com/news/enz-stock-falls-post-q1-134800738.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/enz-stock-falls-post-q1-134800738.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Enzo Biochem, Inc. ENZ have tumbled 30.9% since the release of its earnings report for the quarter ended Oct. 31, 2024. This compares unfavorably with the S&P 500 Index's 2.9% decline over ...</p>\n\n<a href=\"https://finance.yahoo.com/news/enz-stock-falls-post-q1-134800738.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"POST","symbol_name":"Post Holdings","start_time":0,"source_url":"https://finance.yahoo.com/news/enz-stock-falls-post-q1-134800738.html","article_id":"2492742461","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_aMgtCHWD_AcEvdCSVRbpA--~B/aD00NDU7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/62a1df11c94046acffed2654620317fb"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492742461","pubTimestamp":1734616080,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Enzo Biochem, Inc. ENZ have tumbled 30.9% since the release of its earnings report for the quarter ended Oct. 31, 2024. This compares unfavorably with the S&P 500 Index's 2.9% decline over the same period. Over the past month, Enzo Biochem's stock recorded a loss of 28.6%, while the S&P 500 posted a modest decrease of 0.4%.Enzo Biochem reported revenues of $6.2 million for first-quarter fiscal 2025, down 20.4% from $7.8 million a year ago, primarily due to reduced orders from significant clinical market customers and the absence of a large industrial order seen in the prior year. The company’s net loss from continuing operations narrowed to $3.1 million, or $0.07 per share, in first-quarter fiscal 2025 compared with $5.7 million, or $0.11 per share, in the year-ago period.Enzo Biochem, Inc. price-consensus-eps-surprise-chart | Enzo Biochem, Inc. Quote","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"POST":"Post Holdings","ENZ":"恩佐生化"},"translate_title":"由于收入和需求挑战，ENZ股价在第一季度盈利后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ENZ":1,"POST":1},"content_text":"Shares of Enzo Biochem, Inc. ENZ have tumbled 30.9% since the release of its earnings report for the quarter ended Oct. 31, 2024. This compares unfavorably with the S&P 500 Index's 2.9% decline over the same period. Over the past month, Enzo Biochem's stock recorded a loss of 28.6%, while the S&P 500 posted a modest decrease of 0.4%.\nRevenue and Earnings Performance\nEnzo Biochem reported revenues of $6.2 million for first-quarter fiscal 2025, down 20.4% from $7.8 million a year ago, primarily due to reduced orders from significant clinical market customers and the absence of a large industrial order seen in the prior year. The company’s net loss from continuing operations narrowed to $3.1 million, or $0.07 per share, in first-quarter fiscal 2025 compared with $5.7 million, or $0.11 per share, in the year-ago period.\nTotal operating costs in the quarter decreased 25.9% year over year to $9.8 million, driven by lower research and development (R&D), selling, general and administrative (SG&A) and legal expenses. Gross margins declined to 41% from 44% due to inventory disposals owing to a portfolio optimization initiative.\nFind the latest EPS estimates and surprises on Zacks Earnings Calendar.\nOther Key Business Metrics\nIn the fiscal first quarter, R&D spending declined 33.8% year over year to $0.6 million, reflecting a strategic focus on manufacturing rather than new research initiatives. SG&A expenses fell 30.3% year over year to $4.9 million due to lower severance costs, reduced share-based compensation for executives and a decrease in bonus accruals. Legal expenses in first-quarter fiscal 2025 decreased 57.4% year over year to $0.5 million as the company moved past litigation related to ransomware attacks and executive disputes from the prior year.\nThe company recorded foreign exchange losses of $0.2 million in the fiscal first quarter, a marked improvement from the $1 million loss in the prior year, reflecting less volatility in currency movements. Interest income decreased 36.5% to $0.6 million from $0.9 million in the same period last year, attributable to a lower cash balance and declining interest rates.\nEnzo Biochem's geographic revenue performance for the quarter ended Oct. 31, 2024, reflects declines across all regions compared to the same period last year. Revenues from the United States fell 18.8% to $3.8 million in first-quarter fiscal 2025 from $4.6 million. Revenues from Europe plunged 22.2% to $1.7 million in the fiscal first quarter from $2.1 million a year ago.\nRevenues from Asia Pacific decreased 24% to $0.8 million in the fiscal first quarter from $1 million. This broad-based decline is attributed to weakened market demand across all customer bases, exacerbated by general headwinds in the life sciences tools sector.\n\nEnzo Biochem, Inc. Price, Consensus and EPS Surprise\n  \nEnzo Biochem, Inc. price-consensus-eps-surprise-chart | Enzo Biochem, Inc. Quote\n\nManagement Commentary and Influencing Factors\nManagement highlighted a challenging demand environment in the life sciences tools sector, which weighed on revenues across all geographic regions. Despite these headwinds, the company implemented cost containment measures, optimizing its portfolio and controlling discretionary spending. A $5 million release from an escrow account related to the 2023 Labcorp asset sale bolstered liquidity. However, cash and equivalents fell to $47.7 million as of Oct. 31, 2024, from $52.4 million as of July 31, 2024, due to operating losses and liability payments.\nGuidance and Outlook\nWhile specific guidance was not provided, management expressed confidence in the company's ability to meet operational requirements for at least the next 12 months based on available working capital of $36.3 million. Strategic initiatives to enhance sales and marketing were noted as areas of ongoing investment, despite current macroeconomic pressures.\nOther Developments\nNo acquisitions, divestitures, or significant restructuring activities were reported during the quarter. However, the company settled multiple legal disputes stemming from a 2023 ransomware attack and continues to address related regulatory inquiries. Additionally, Enzo Biochem is pursuing the dismissal of ongoing class-action litigation, which may be finalized by early 2025.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEnzo Biochem, Inc. (ENZ) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492742461"}